33566
document
Randomized study of chlorambucil ( CB ) compared to interferon ( alfa-2b ) combined with CB in low-grade non-Hodgkin 's lymphoma : an interim report of a randomized study . Non-Hodgkin 's Lymphoma Cooperative Study Group . Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin 's lymphoma ( NHL ) , especially with the nodular form of the disease . The present study enrolled 70 NHL patients who received either chlorambucil ( CB ; 10 mg/day ) or CB plus interferon alfa-2b ( 5 million units ( MU ) /m2 subcutaneously three times a week ) . Among 63 evaluable patients , similar response rates ( 62.1 % and 64.7 % respectively ) were recorded for the treatment arms . In patients receiving no maintenance therapy , those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone . During maintenance therapy with interferon alfa-2b , no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy . A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission .
33567
Intervention_Pharmacological
chlorambucil
33568
Intervention_Pharmacological
interferon
33569
Intervention_Pharmacological
CB
33570
Intervention_Pharmacological
Alpha interferon
33571
Intervention_Pharmacological
chlorambucil
33572
Intervention_Pharmacological
CB plus interferon alfa-2b
33573
Intervention_Pharmacological
interferon alfa-2b
33574
Intervention_Physical
interferon maintenance therapy
33575
Intervention_Pharmacological
chlorambucil
33576
Intervention_Pharmacological
interferon
33577
Outcome_Physical
incidence of relapse
33578
Outcome_Physical
occurrence of relapse
33579
Participant_Condition
non-Hodgkin 's lymphoma
33580
Participant_Condition
Non-Hodgkin 's Lymphoma
33581
Participant_Sample-size
70
33582
Participant_Sample-size
63
33583
Participant_Condition
no maintenance therapy
33584
Participant_Condition
no maintenance therapy